Santa Monica, CA, United States of America

Steven B Kanner

USPTO Granted Patents = 40 

 

 

Average Co-Inventor Count = 6.8

ph-index = 6

Forward Citations = 149(Granted Patents)


Location History:

  • Princeton, NJ (US) (2004 - 2009)
  • Santa Monica, CA (US) (2007 - 2015)
  • Madison, WI (US) (2017 - 2020)
  • Berkeley, CA (US) (2019 - 2023)

Company Filing History:


Years Active: 2004-2025

Loading Chart...
Loading Chart...
Loading Chart...
40 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Steven B. Kanner

Introduction

Steven B. Kanner, based in Santa Monica, California, is a prominent inventor known for his extensive contributions to the field of biotechnology, specifically in cancer detection and treatment. With a remarkable portfolio of 26 patents, Kanner has pushed the boundaries of scientific innovation, particularly through his work in nucleic acid research.

Latest Patents

Kanner's latest patents focus on a novel nucleic acid and its corresponding protein, referred to as 158P1D7. This innovative invention is significant for its application in the treatment and detection of bladder and various other cancers. The detailed descriptions of these patents highlight Kanner's commitment to advancing diagnostic and therapeutic methods that can effectively manage cancers expressing 158P1D7 and its variants.

Career Highlights

Throughout his career, Steven B. Kanner has worked with several well-known companies in the pharmaceutical and biotechnology sectors. Notably, he has held roles at Agensys, Inc., and Bristol-Myers Squibb Company, where he contributed to significant advancements in cancer treatment. His innovative spirit and dedication to research have established him as a respected figure in the industry.

Collaborations

Kanner's collaborative efforts have also been noteworthy. He has worked alongside esteemed colleagues such as Juan J. Perez-Villar and Aya Jakobovits. These collaborations have fostered an environment of creativity and knowledge exchange, further propelled the progress of their shared research objectives.

Conclusion

Steven B. Kanner's dedication to innovation in biotechnology is evident through his impressive patent portfolio and collaborative projects. His work on the 158P1D7 protein illustrates his commitment to addressing critical challenges in cancer treatment and detection. As the field continues to evolve, Kanner's contributions will undoubtedly pave the way for future advancements that can improve patient outcomes in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…